Zvonko Miličević

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 966 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

Medicine, Endocrinology, Pharmacology +17

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 376 citations

Medicine, Endocrinology, Pharmacology +14

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Itamar Raz, Peter W.F. Wilson, Krzysztof Strojek et al. · Diabetes Care · 2009 · 353 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Melissa K. Thomas, Amir Nikooienejad, Ross Bray et al. · The Journal of Clinical Endocrinology & Metabolism · 2020 · 320 citations · Full text

Medicine, Endocrinology, Pharmacology +17